EC
AHCO icon

Eminence Capital’s AdaptHealth AHCO Stock Holding History

Eminence Capital’s Portfolio AHCO Stock Details AHCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-447,616
Closed -$8.07M – 63
2022
Q2 		$8.07M Buy
447,616
+121,525
+37% +$1.97M 0.16% 61
2022
Q1 		$5.23M Buy
+326,091
New +$5.86M 0.06% 66

Other funds holding AHCO

OCA
OEP Capital Advisors New York $194M AUM 9.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
SkyKnight Capital San Francisco, California $107M AUM 9.69% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eminence Capital's AHCO Position: Q3 2022 in Review

Eminence Capital sold out of AdaptHealth (AHCO) in Q3 2022, closing a stake of 447,616 shares — an estimated $8.07M sold.

Eminence Capital first reported a position in AHCO in Q1 2022 and held it in 2 quarters. The position peaked at $8.07M in Q2 2022. 184 funds tracked by Wall St. Rank hold AHCO as of Q3 2022.

  • Eminence Capital reported no remaining AdaptHealth position as of Q3 2022 after selling out during the quarter.
  • Eminence Capital sold 447,616 AdaptHealth shares in Q3 2022, an estimated $8.07M.
  • Eminence Capital first reported a position in AdaptHealth in Q1 2022 and held it in 2 quarters.
  • Eminence Capital's AdaptHealth position peaked at $8.07M in Q2 2022.
  • 184 funds tracked by Wall St. Rank held AdaptHealth as of Q3 2022.

Based on Eminence Capital's 13F filing for Q3 2022, filed 14 Nov 2022.